Global First | NMPA Accepts IND Application for Mabwell's Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311
SHANGHAI, April 16, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) has accepted the Investigational...
FDA Accepts NDA for TLX101-Px (Pixclara®)
MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Company's...